



ENTRY INTO SUPPLEMENTAL LETTER OF INTENT WITH CHINA MERCHANTS SHEKOU INDUSTRIAL ZONE HOLDINGS CO., LTD.

1. INTRODUCTION

The Board of Directors (the “**Board**”) refers to the announcement made by the Company on 12 December 2018 in relation to the entry into the non-binding letter of intent (the “**LOI**”) with China Merchants Shekou Industrial Zone Holdings Co., Ltd. (“**CMSK**”) to jointly develop, operate and manage a high-end international hospital in Prince Bay, Shekou, Shenzhen, the People’s Republic of China (the “**Previous Announcement**”).

Unless otherwise defined, all capitalised items herein shall have the same meaning as ascribed to them in the Previous Announcement.

2. ENTRY INTO SUPPLEMENTAL LOI

As set out in the Previous Announcement, the LOI shall terminate on the earlier of (i) the entry into the definitive agreement(s) which shall supersede the LOI; or (ii) 30 June 2019 or such later date as may be mutually agreed in writing by the parties (“**Expiry Date**”).

The Board wishes to announce that the Company and CMSK have today entered into a supplemental letter of intent (“**Supplemental LOI**”), pursuant to which it was agreed that the Expiry Date under the LOI shall be extended to 31 December 2019 or such later date as may be mutually agreed in writing by the parties.

All other terms of the LOI remain unchanged.

3. FURTHER ANNOUNCEMENTS

The Company will make further announcement(s) as and when there are any material updates or developments in relation to the Proposed Hospital Project.

4. CAUTIONARY STATEMENT

Shareholders and potential investors are advised to read this announcement and any further announcements by the Company carefully and to exercise caution when dealing in the shares of the Company. Shareholders and potential investors should note that the Proposed Hospital Project is subject to, *inter alia*, the execution of the definitive agreement(s). Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

By Order of the Board
OUE Lippo Healthcare Limited

Mr Yet Kum Meng
Chief Executive Officer and Executive Director
31 May 2019

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalyst.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

OUE Lippo Healthcare Limited
Company Registration No. 201304341E
(In receivership over charged shares in certain subsidiaries)
6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809
T: +65 6578 9188 F: 64794647 www.ouelh.com